Success Stories: NIW and EB1-A Approvals Received for a Research Postdoc Fellow in Biomedical Science from China, Thanks to NAILG’s Team of Experts
Client’s Testimonial:
“Thanks for your help on my case!”
On May 4th, 2022 and August 23rd, 2022, we received another EB2-NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approval for a Research Postdoc Fellow in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Research Postdoc Fellow
Country of Origin: China
State of Residence at the Time of Filing: Texas
Approval Notice Date: May 4th, 2022 (NIW) and August 23rd, 2022 (EB-1A)
Processing Time: 3 months, 16 days (NIW) and 13 days (EB-1A) (Premium Processing Requested)
Case Summary:
“Cancer is one of the leading causes of death around the world, as it is responsible for approximately 10,000,000 global deaths on an annual basis. In addition, neurodegenerative diseases affect nearly 50,000,000 people worldwide. Further, these numbers are only expected to increase as the global population continues to grow in numbers and age. [Client’s] research is essential to accurately determine the mechanisms underpinning the development of these diseases. As a result, her work advances ongoing efforts in the field aimed at reducing the impact of cancer and neurodegenerative diseases in the United States and around the world.”
This is a section taken from a letter of support written by a recommending expert in the field of biomedical science for a postdoctoral fellow from China. She held a Ph.D. in biological sciences and had been working in the area for several years already, which had given her precious experience lending to her credibility as well.
She was one of the few leading disease genetics and cellular therapeutics experts in biomedical science, and she has achieved a consistent and notable record of success and influence in these areas of study. She is especially well-known for her work investigating stem cell-based cancer therapeutics and developing functional biomarkers for cancer treatment. The field has recognized her authority by inviting her to review and evaluate the work of her peers no fewer than 65 times.
She has also actively engaged her peers in the field of biomedical science by authoring and co-authoring 27 peer-reviewed articles and 1 provisional patent that have been published in international journals and have been cited 260 times in at least 33 countries according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of biomedical science.
These factors weighed in her favor when we prepared her case file for NIW (National Interest Waiver) and later her EB1-A (Alien of Extraordinary Ability) approval. We made sure that both of her petitions were customized and that they contained every necessary information that would be needed to prove their extraordinary ability or their worthiness for the United States. Once the petitions were ready, we were certain that they would not be rejected. So when first her NIW and later her EB1-A approvals came through, we felt proud of having worked with her on this case. We are glad that due to our work and the expedited plan of premium processing, her EB1-A could be approved in just 13 days.
Our team wishes her the best in future endeavors and thanks her for choosing our firm to represent her in these cases.